Journal of Psychopharmacology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

SAGETRACK

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0269881106067255v1
0269881106067255v2
21/4/384    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fradley, R. L.
Right arrow Articles by Atack, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fradley, R. L.
Right arrow Articles by Atack, J. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
This version was published on June 1, 2007
Journal of Psychopharmacology, Vol. 21, No. 4, 384-391 (2007)
DOI: 10.1177/0269881106067255

Differential contribution of GABAA receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands

Rosa L. Fradley

Merck, Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, UK

Martin R. Guscott

Merck, Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, UK

Sharlene Bull

Merck, Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, UK

David J. Hallett

Merck, Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, UK

Simon C. Goodacre

Merck, Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, UK

Keith A. Wafford

Merck, Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, UK

ELizabeth M. Garrett

Merck, Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, UK

Richard J. Newman

Merck, Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, UK

Gillian F. O'Meara

Merck, Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, UK

Paul J. Whiting

Merck, Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, UK

Thomas W. Rosahl

Merck, Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, UK

Gerard R. Dawson

Merck, Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, UK

David S. Reynolds

Merck, Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, UK

John R. Atack

Merck, Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, UK, JAtack{at}prdus.jnj.com

Non-selective benzodiazepines, such as diazepam, interact with equivalent affinity and agonist efficacy at GABAA receptors containing either an {alpha}1, {alpha}2, {alpha}3 or {alpha}5 subunit. However, which of these particular subtypes are responsible for the anticonvulsant effects of diazepam remains uncertain. In the present study, we examined the ability of diazepam to reduce pentylenetetrazoLe (PTZ)-induced and maximal electroshock (MES)-induced seizures in mice containing point mutations in single ({alpha}1H101R, {alpha}2H101R or {alpha}5H105R) or multiple ({alpha}125H->R) {alpha} subunits that render the resulting GABAA receptors diazepam-insensitive. Furthermore, the anticonvulsant properties of diazepam, the {alpha}1- and {alpha}3-selective compounds zoLpidem and TP003, respectively, and the {alpha}2/{alpha}3 preferring compound TP13 were studied against PTZ-induced seizures. In the transgenic mice, no single subtype was responsible for the anticonvulsant effects of diazepam in either the PTZ or MES assay and neither the {alpha}3 nor {alpha}5 subtypes appeared to confer anticonvulsant activity. Moreover, whereas the {alpha}1 and {alpha}2 subtypes played a modest role with respect to the PTZ assay, they had a negligible role in the MES assay. With respect to subtype-selective compounds, zolpidem and TP003 had much reduced anticonvulsant efficacy relative to diazepam in both the PTZ and MES assays whereas TP13 had high anticonvulsant efficacy in the PTZ but not the MES assay. Taken together, these data not only indicate a role for {alpha}2-containing GABAA receptors in mediating PTZ and MES anticonvulsant activity but also suggest that efficacy at more than one subtype is required and that these subtypes act synergistically.

Key Words: pentylenetetrazole • maximal electroshock • mouse • knock-in mice • GABAA • epilepsy • benzodiazepines


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?